People struggling with cancer may undergo an allogeneic stem cell transplant, which involves replacing unhealthy stem cells with new ones. Because using a patient’s own stem cell can be unpredictable, many patients use donated bone marrow stem cells for this procedure. If successful, the procedure can help fight off cancer and leukemia. Find out what allogeneic stem cell transplant is, including how it works, as well as the risks and benefits involved with the procedure. [Read more…]
Can Asthma Treatment Be Achieved Through Stem Cell Therapy?
Progress with regenerative medicine is supporting the development of a new type of asthma treatment that has the potential to reduce asthma attacks and repair lung damage.
In this article:
Direct Cell Reprogramming: What Is It and How Does It Work?
Direct cell reprogramming is the in vitro (laboratory) or in vivo (in the body) reprogramming of somatic cells into other cell types without the need for an intermediate pluripotent state. Another term for direct cell reprogramming is transdifferentiation, which is the direct conversion of one differentiated cell type into another.
There has been tremendous activity over the last decade in the development of stem cells therapeutics, which have relied on stem cell differentiation protocols, as well as techniques for direct cell reprogramming. Today, there are over 7,149+ stem cell trials registered on ClinicalTrials.gov and stem cell publications have increased dramatically in recent years, recently surpassing 500,000+ on PubMed.gov.
However, for all their promise, stem cells are yet to deliver on this therapeutic potential, and this failure appears due to various technical challenges that still need to be overcome. [Read more…]
Applied StemCell Demonstrates Efficient Knock-In of a 50 kb DNA Construct into Human iPSCs Using TARGATT™ Technology
MILPITAS, Calif., Nov. 11, 2025 – Applied StemCell, Inc. (ASC), today announced the successful knock-in of a 50 kilobase (kb) multifunctional DNA insert into human induced pluripotent stem cells (iPSCs) using its proprietary TARGATT™ technology. The achievement establishes a new benchmark for the size and complexity of genetic payloads that can be efficiently and site-specifically integrated into the human genome. [Read more…]
Bridging the Gap: Streamlining iPSC-Derived Cell Line Development from Donor Cells to MCB
Allogeneic iPSC-derived therapies hold immense promise, offering scalable, off-the-shelf solutions for a wide spectrum of diseases. However, the journey from donor cells to a gene edited, clinically compliant GMP Master Cell Bank (MCB) is fraught with challenges and is particularly vulnerable to risks stemming from misaligned early development.
A major bottleneck seen in the majority of iPSC therapeutic programs arises when development teams continue to rely on R&D grade cell lines to confirm proof-of-concept, conduct preclinical animal studies, and to start process & analytical development. [Read more…]
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 202
- Next Page »